Article Versions Notes

Tsai C-Y, Ko H-J, Chiou S-J, Lai Y-L, Hou C-C, Javaria T, Huang Z-Y, Cheng T-S, Hsu T-I, Chuang J-Y, et al. NBM-BMX, an HDAC8 Inhibitor, Overcomes Temozolomide Resistance in Glioblastoma Multiforme by Downregulating the β-Catenin/c-Myc/SOX2 Pathway and Upregulating p53-Mediated MGMT Inhibition. International Journal of Molecular Sciences. 2021; 22(11):5907. https://doi.org/10.3390/ijms22115907

Tsai, Cheng-Yu, Huey-Jiun Ko, Shean-Jaw Chiou, Yu-Ling Lai, Chia-Chung Hou, Tehseen Javaria, Zi-Yi Huang, Tai-Shan Cheng, Tsung-I Hsu, Jian-Ying Chuang, and et al. 2021. "NBM-BMX, an HDAC8 Inhibitor, Overcomes Temozolomide Resistance in Glioblastoma Multiforme by Downregulating the β-Catenin/c-Myc/SOX2 Pathway and Upregulating p53-Mediated MGMT Inhibition" International Journal of Molecular Sciences 22, no. 11: 5907. https://doi.org/10.3390/ijms22115907

Tsai, C. -Y., Ko, H. -J., Chiou, S. -J., Lai, Y. -L., Hou, C. -C., Javaria, T., Huang, Z. -Y., Cheng, T. -S., Hsu, T. -I., Chuang, J. -Y., Kwan, A. -L., Chuang, T. -H., Huang, C. -Y. F., Loh, J. -K., & Hong, Y. -R. (2021). NBM-BMX, an HDAC8 Inhibitor, Overcomes Temozolomide Resistance in Glioblastoma Multiforme by Downregulating the β-Catenin/c-Myc/SOX2 Pathway and Upregulating p53-Mediated MGMT Inhibition. International Journal of Molecular Sciences, 22(11), 5907. https://doi.org/10.3390/ijms22115907